Inhibrx Biosciences (INBX) Competitors $27.88 +0.48 (+1.75%) Closing price 04:00 PM EasternExtended Trading$27.88 0.00 (0.00%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. EVO, AVDL, PAHC, XERS, CVAC, ELVN, CALT, COLL, NTLA, and PHVSShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Evotec (EVO), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Xeris Biopharma (XERS), CureVac (CVAC), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Evotec Avadel Pharmaceuticals Phibro Animal Health Xeris Biopharma CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) Collegium Pharmaceutical Intellia Therapeutics Pharvaris Evotec (NASDAQ:EVO) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Which has more risk and volatility, EVO or INBX? Evotec has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Does the media favor EVO or INBX? In the previous week, Inhibrx Biosciences had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Inhibrx Biosciences and 1 mentions for Evotec. Inhibrx Biosciences' average media sentiment score of 0.79 beat Evotec's score of 0.63 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Evotec Positive Inhibrx Biosciences Positive Is EVO or INBX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Evotec-20.14% -16.94% -8.14% Inhibrx Biosciences N/A -137.83%-76.31% Which has better earnings and valuation, EVO or INBX? Inhibrx Biosciences has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.45-$212.18MN/AN/AInhibrx Biosciences$200K2,018.51$1.69B-$10.58-2.64 Do analysts rate EVO or INBX? Evotec currently has a consensus target price of $5.40, suggesting a potential upside of 53.85%. Given Evotec's stronger consensus rating and higher probable upside, equities analysts plainly believe Evotec is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in EVO or INBX? 5.8% of Evotec shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryEvotec and Inhibrx Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$403.70M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-2.6421.2231.3126.60Price / Sales2,018.51390.30461.30121.37Price / Cash0.2244.4437.7659.36Price / Book5.898.0710.026.67Net Income$1.69B-$54.08M$3.27B$265.59M7 Day Performance15.40%2.26%3.17%3.42%1 Month Performance13.47%3.42%4.34%1.09%1 Year Performance99.71%18.61%44.11%23.85% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences1.6385 of 5 stars$27.88+1.8%N/A+93.1%$403.70M$200K-2.64166EVOEvotec1.5842 of 5 stars$3.68-2.1%$5.40+46.7%-8.2%$1.34B$862.40M0.004,827AVDLAvadel Pharmaceuticals2.7163 of 5 stars$13.48-1.5%$18.67+38.5%-5.9%$1.33B$169.12M-449.3370News CoveragePAHCPhibro Animal Health3.4341 of 5 stars$31.25+1.9%$24.40-21.9%+52.9%$1.24B$1.19B40.061,940News CoverageEarnings ReportGap UpXERSXeris Biopharma3.4091 of 5 stars$7.36-4.2%$6.58-10.6%+177.4%$1.24B$203.07M-35.05290Positive NewsCVACCureVac4.5611 of 5 stars$5.45-0.5%$6.83+25.4%+64.0%$1.23B$579.18M5.92880Positive NewsEarnings ReportELVNEnliven Therapeutics2.768 of 5 stars$19.75-2.3%$41.20+108.6%-8.3%$1.20BN/A-9.8850CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180COLLCollegium Pharmaceutical3.0932 of 5 stars$38.19+1.2%$42.33+10.8%+2.6%$1.19B$631.45M36.72210Positive NewsNTLAIntellia Therapeutics4.5411 of 5 stars$10.73-2.4%$29.05+170.8%-50.2%$1.18B$52.86M-2.29600Positive NewsPHVSPharvaris2.6095 of 5 stars$22.16-0.6%$35.60+60.6%+28.5%$1.17BN/A-6.6030 Related Companies and Tools Related Companies Evotec Alternatives Avadel Pharmaceuticals Alternatives Phibro Animal Health Alternatives Xeris Biopharma Alternatives CureVac Alternatives Enliven Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives Pharvaris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access